Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform focused on developing universally implantable bioengineered human tissues, is set to present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at Nasdaq World Headquarters in New York. Laura Niklason, M.D., Ph.D., Founder, President, and CEO of Humacyte, will represent the company in a presentation at 12:30 p.m. EST. Attendees will have the opportunity for one-on-one meetings with management following the presentation. A webcast of the event can be accessed via Humacyte's website, where a replay will also be available afterwards.

Humacyte is pioneering a revolutionary approach to medicine through its advanced tissue constructs, aimed at treating a variety of diseases, injuries, and chronic conditions. The company’s notable achievement includes the FDA approval of its acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024. Currently, Humacyte is advancing ATEVs through late-stage clinical trials for several applications, including arteriovenous access for hemodialysis and peripheral artery disease. Furthermore, the company is in preclinical development phases for additional applications such as coronary artery bypass grafts and pediatric heart surgery.

Humacyte's 6mm ATEV for AV access has been awarded the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, alongside receiving Fast Track designation for its innovation in regenerative medicine. The company has also garnered priority designation by the U.S. Secretary of Defense for its ATEV in treating vascular trauma. Humacyte continues to position itself at the forefront of biotechnological advancements, as it explores further applications and solidifies its role in transforming medical practices. For further details, visit www.Humacyte.com.

Humacyte, Inc. (Nasdaq: HUMA) is poised to leverage its presentation at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, as a platform to showcase its unique position within the biotechnology sector. As a company specializing in universally implantable, bioengineered human tissues, the significance of its recent FDA approval for the acellular tissue engineered vessel (ATEV) for vascular trauma cannot be overstated.

The market's response to the company's advancements in biomanufacturing and the potential applications of its technology—ranging from treatment for hemodialysis to chronic conditions like type 1 diabetes—could provide a catalyst for stock performance. Investors should pay close attention to the outcomes of ongoing late-stage trials and preclinical developments, as successful results could lead to new commercial opportunities and additional FDA designations.

Furthermore, the fact that Humacyte's ATEV product has received multiple designations, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, underscores its potential for expansion within the medical community. These designations, along with priority treatment options for U.S. military applications, may enhance Humacyte's reputation and visibility, building significant investor confidence.

As the company's management engages with investors through one-on-one meetings and a scheduled fireside chat, market participants should gauge how executives articulate their strategic vision and timelines for upcoming milestones in product development.

In conclusion, while maintaining a cautious approach given the volatility typically associated with biotech investments, Humacyte presents an intriguing opportunity for growth within the sector. Monitoring the outcomes of its ongoing clinical trials and strategic communications from the conference will be critical for both short-term and long-term investment decisions.